Currently, non-IgG antibodies have gained extraordinary importance in clinical diagnosis and therapy because of their inherent advantages. Equipped with the world-leading antibody development platform and professional scientific staffs, Creative Biolabs is proud to support high-efficiency non-IgG antibody development projects for our customers all over the world. At present, we can provide one-stop non-IgG development services, including antibody production, purification, characterization, modification, etc. IgM is one important class of therapeutic antibodies that we provide as promising treatments for esophagus carcinoma.
Brief Introduction of Esophagus Carcinoma
Esophageal cancer (EC) is a serious malignancy arising from the esophagus, a tube-like structure that runs from your throat to your stomach. EC has become a growing health concern with regards to mortality and prognosis. EC is classified into several types according to the cells that are involved, including esophageal adenocarcinoma (EAC, the most common form of EC in the United States), squamous cell carcinoma (SCC, the most common histological type of EC worldwide) and other rare types. It is well-recognized that smoking, heavy alcohol use, and Barrett esophagus (BE) can increase the risks of EC. Weight loss and painful or difficult swallowing are typical symptoms of EC.
Multimodality therapies are recommended for EC treatment, mainly including surgery, radiation, and chemotherapy. Effective tumor markers of EC and their antibodies are an advancing area of research that could potentially lead to earlier diagnosis as well as play a part in assessing tumor response to therapy. In addition to approved IgG therapeutic monoclonal antibodies, non-IgG therapeutic antibodies, mainly IgM antibodies, have attracted numerous attention in the pharmaceutical field worldwide recently.
IgM Antibodies for Esophagus Carcinoma
Natural IgM antibodies play an important role in immunosurveillance mechanisms against epithelial tumors in humans, including EC. Prof. Farinati demonstrated that the immune-complexed form of squamous cell carcinoma antigen [SCCA-immunoglobulin (Ig)M] can be used in the identification of patients at risk for BE and EAC. It was reported that the serological levels of SCCA-IgM are significantly higher in patients with BE or EAC compared to controls. Additionally, in patients with SCCA-IgM levels above the cutoff, the relative risk of harboring BE or EAC is 33 times higher, indicating the importance of SCCA-IgM in identifying the patients at risk for BE or EAC and to stratifying subjects with BE in different risk categories. This screening might improve the surveillance protocols currently used on patients at risk for BE or EAC and may reduce the number of endoscopies and their associated costs.
Fig.1 Apoptosis by lipid accumulation (IgM induced). (Brandlein, 2004)
Features of Our Services
- High reproducibility
- One-stop service with full customization to meet specific demands
- High-quality products with stronger affinity and effector functions
- Competitive price and best after-sale service
As a pioneer in the non-IgG antibodies research, Creative Biolabs can provide a full spectrum of non-IgG therapeutic antibodies development services. We are pleased to utilize our extensive experience and advanced platform to offer high-quality services and diversified products to satisfy clients' demands for various applications. If you are interested in our services, please do not hesitate to contact us for more details or a quote.
Reference
- Brandlein, S.; Vollmers, H.P. Natural IgM antibodies, the ignored weapons in tumor immunity. HISTOLOGY AND HISTOPATHOLOGY. 2004, 19: 897-905.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
